Brilinta Recommended in Updated ACCF/AHA Guidelines

Share this article:
BRILINTA (ticagrelor) 90mg tablets by AstraZeneca
BRILINTA (ticagrelor) 90mg tablets by AstraZeneca

AstraZeneca announced that the panel of experts from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) has updated their guidelines to include a Class I recommendation for use of Brilinta (ticagrelor) tablets in patients with ST-elevation myocardial infarction (STEMI) managed invasively.

A loading dose of ticagrelor 180mg is now one of the recommended options that is to be given as early as possible or at time of primary percutaneous coronary intervention (PCI) to patients with STEMI. Also, a maintenance dose of ticagrelor 90mg twice daily for one year is one of the recommended options for patients with STEMI who receive a stent during primary PCI. The use of concomitant aspirin is recommended before and after primary PCI.

Brilinta is a P2Y12 platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina or non-ST-elevation myocardial infarction [MI] or ST-elevation MI).

For more information call (800) 236-9933 or visit www.brilinta.com.

Share this article:

Related Resources